Drug Profile
NYX 2925
Alternative Names: NYX-2925Latest Information Update: 03 May 2023
Price :
$50
*
At a glance
- Originator Aptinyx
- Class Analgesics; Aza compounds; Small molecules; Spiro compounds
- Mechanism of Action NMDA receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic neuropathies; Fibromyalgia; Neurological disorders
Most Recent Events
- 12 Aug 2022 Efficacy and adverse events data from a phase IIb trial in fibromyalgia released by Aptinyx
- 16 Jun 2022 Aptinyx completes a phase IIb trial in Fibromyalgia in USA (PO, Capsule) (NCT04147858)
- 07 Apr 2022 Efficacy and adverse events data from a phase IIb trial in Diabetic neuropathies released by Aptinyx